BRPI0914504B8 - uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv - Google Patents

uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv

Info

Publication number
BRPI0914504B8
BRPI0914504B8 BRPI0914504A BRPI0914504A BRPI0914504B8 BR PI0914504 B8 BRPI0914504 B8 BR PI0914504B8 BR PI0914504 A BRPI0914504 A BR PI0914504A BR PI0914504 A BRPI0914504 A BR PI0914504A BR PI0914504 B8 BRPI0914504 B8 BR PI0914504B8
Authority
BR
Brazil
Prior art keywords
piv
prophylactic
therapeutic treatment
individual
renal
Prior art date
Application number
BRPI0914504A
Other languages
English (en)
Inventor
Annette Duggan Karen
Original Assignee
Vectus Biosystems Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008905378A external-priority patent/AU2008905378A0/en
Application filed by Vectus Biosystems Pty Ltd filed Critical Vectus Biosystems Pty Ltd
Publication of BRPI0914504A2 publication Critical patent/BRPI0914504A2/pt
Publication of BRPI0914504B1 publication Critical patent/BRPI0914504B1/pt
Publication of BRPI0914504B8 publication Critical patent/BRPI0914504B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método de tratamento profilático ou terapêutico da doença renal crônica em um indivíduo, método de tratamento profilático ou terapêutico da insuficiência renal em um indivíduo , método de tratamento profilático ou terapêutico da fibrose renal em um indivíduo, método para reduzir os níveis, inibir ou reduzir a produção dos mediadores profibróticos em um indivíduo em risco de desenvolver ou que têm a doença renal crônica, a insuficiência renal e/ou a fibrose renal estabelecidas, método para reduzir a formação de colágeno ou intensificar a degradação do colágeno nos rins de um indivíduo, peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv, composição para o tratamento profilático ou terapêutico da doença renal crônica, composição para o tratamento profilático ou terapêutico da insuficiência renal e composição para o tratamento profilático ou terapêutico da fibrose renal a invenção refere-se às composições que compreendem o peptídeo intestinal vasoativo (piv) ou os fragmentos deste, e à utilização de tais composições no tratamento da doença renal, em particular, da fibrose renal, e em outras condições associadas.
BRPI0914504A 2008-10-17 2009-10-16 uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv BRPI0914504B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008905378 2008-10-17
AU2008905378A AU2008905378A0 (en) 2008-10-17 Compositions and methods for treatment of kidney disorders
PCT/AU2009/001367 WO2010042997A1 (en) 2008-10-17 2009-10-16 Compositions and methods for treatment of kidney disorders

Publications (3)

Publication Number Publication Date
BRPI0914504A2 BRPI0914504A2 (pt) 2016-01-12
BRPI0914504B1 BRPI0914504B1 (pt) 2020-11-10
BRPI0914504B8 true BRPI0914504B8 (pt) 2021-05-25

Family

ID=42106133

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914504A BRPI0914504B8 (pt) 2008-10-17 2009-10-16 uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv

Country Status (18)

Country Link
US (2) US8569235B2 (pt)
EP (1) EP2349320B1 (pt)
JP (1) JP2012505835A (pt)
KR (1) KR101671406B1 (pt)
CN (1) CN102186496A (pt)
AU (1) AU2009304595B2 (pt)
BR (1) BRPI0914504B8 (pt)
CA (1) CA2740989C (pt)
DK (1) DK2349320T3 (pt)
ES (1) ES2603963T3 (pt)
IL (2) IL212353A0 (pt)
MX (1) MX336384B (pt)
MY (1) MY160560A (pt)
NZ (2) NZ603602A (pt)
RU (1) RU2519124C2 (pt)
SG (1) SG10201501316VA (pt)
WO (1) WO2010042997A1 (pt)
ZA (1) ZA201103572B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
CN101384272B (zh) 2005-12-20 2013-05-01 杜克大学 用于递送具有增强的药理性质的活性剂的方法和组合物
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP3412300A1 (en) 2008-06-27 2018-12-12 Duke University Therapeutic agents comprising elastin-like peptides
CN102186496A (zh) * 2008-10-17 2011-09-14 维克特斯生物系统有限公司 治疗肾功能紊乱的组合物和方法
NZ595726A (en) * 2009-04-02 2013-06-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of aortic fibrosis
ES2606140T3 (es) * 2010-10-01 2017-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos para predecir la progresión y tratar una enfermedad renal crónica en un paciente
CN104130663B (zh) * 2014-06-27 2017-01-04 南安市永腾技术咨询有限公司 一种用于包装机的金属防腐漆及其制备方法
DK3271326T3 (da) * 2015-03-18 2021-01-25 Vectus Biosystems Ltd Sammensætninger til behandling af nyre- og/eller leversygdom
US9779043B2 (en) 2015-11-16 2017-10-03 International Business Machines Corporation Techniques for handling queued interrupts in a data processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105765A2 (en) * 2002-06-12 2003-12-24 The Board Of Trustees Of The University Of Illinois Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds
ES2368565T3 (es) 2002-11-27 2011-11-18 Ils Inc. Péptidos y composiciones medicinales que contienen los mismos.
KR20140057411A (ko) * 2004-06-11 2014-05-12 벡투스 바이오시스템즈 피티와이 리미티드 심혈관 질환의 치료를 위한 조성물 및 방법
US9006181B2 (en) * 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
CN102186496A (zh) * 2008-10-17 2011-09-14 维克特斯生物系统有限公司 治疗肾功能紊乱的组合物和方法
NZ595726A (en) * 2009-04-02 2013-06-28 Vectus Biosystems Pty Ltd Compositions and methods for treatment of aortic fibrosis

Also Published As

Publication number Publication date
IL235888A (en) 2017-08-31
DK2349320T3 (en) 2016-09-26
AU2009304595B2 (en) 2015-02-05
KR101671406B1 (ko) 2016-11-01
EP2349320B1 (en) 2016-06-22
JP2012505835A (ja) 2012-03-08
IL212353A0 (en) 2011-06-30
CN102186496A (zh) 2011-09-14
RU2519124C2 (ru) 2014-06-10
US20110218149A1 (en) 2011-09-08
US9238054B2 (en) 2016-01-19
SG10201501316VA (en) 2015-05-28
HK1160598A1 (zh) 2012-08-10
ZA201103572B (en) 2012-01-25
MY160560A (en) 2017-03-15
MX2011004031A (es) 2011-06-27
US8569235B2 (en) 2013-10-29
US20140080758A1 (en) 2014-03-20
NZ603602A (en) 2013-09-27
KR20110095266A (ko) 2011-08-24
EP2349320A4 (en) 2012-12-26
CA2740989A1 (en) 2010-04-22
BRPI0914504A2 (pt) 2016-01-12
NZ592612A (en) 2013-01-25
AU2009304595A1 (en) 2010-04-22
WO2010042997A1 (en) 2010-04-22
ES2603963T3 (es) 2017-03-02
CA2740989C (en) 2016-07-12
MX336384B (es) 2016-01-18
BRPI0914504B1 (pt) 2020-11-10
EP2349320A1 (en) 2011-08-03
RU2011114857A (ru) 2012-11-27

Similar Documents

Publication Publication Date Title
BRPI0914504B8 (pt) uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BRPI0718927A2 (pt) Método de imunização contra os quatro sorotipos da dengue.
BRPI0509331B8 (pt) uso de uma composição de ligação de sódio
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
NO20084368L (no) Stabile emulsjonsformuleringer
PH12015502275A1 (en) Therapuetic uses of empagliflozin
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
BRPI0510142A (pt) compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2009038842A3 (en) Methods and compositions to inhibit edema factor and adenylyl cyclase
BRPI0814899A2 (pt) Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
BR112021024886A2 (pt) Métodos de tratar a doença de fabry em pacientes com insuficiência renal
WO2008016666A3 (en) Certain chemical entities, compositions, and methods
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
PL1965809T3 (pl) Kompozycje do poprawiania zdrowia jelit i użytkowości zwierząt zawierające beta-glukany i alfa-fukany
ATE481094T1 (de) Behandlung von diabetischer nephropathie
BR112013009185A2 (pt) uso de mexiprostil no tratamento de doença inflamatória intestinal e/ou de síndrome do intestino irritável.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINTA A PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 16A RETRIBUICAO ANUAL (VIDE PARECER).

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2850 DE 19-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.